Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without.
The NEW Amarin and NEW Board is On the Right Track – Leading Independent Experts, ISS and Glass Lewis, Agree that Sarissa Representation is Not Warranted .
Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively.
Wall Street analysts expect Amarin Co. plc (NASDAQ:AMRN – Get Rating) to post sales of $104.88 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Amarin’s earnings. The lowest sales estimate is $84.65 million and the highest is $122.00 million. Amarin reported sales of $154.49 million in the […]